Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Corcept Therapeutics and raised the price target from $38 to $67.
September 18, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has increased its price target for Corcept Therapeutics from $38 to $67, maintaining an Overweight rating. This suggests a positive outlook for the stock.
The increase in price target from $38 to $67 by Piper Sandler indicates a strong positive sentiment towards Corcept Therapeutics. Maintaining an Overweight rating suggests that the analyst expects the stock to outperform the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100